TY - JOUR
T1 - A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction
T2 - A randomised, double-blind, parallel-group, placebo-controlled study in Australian men
AU - McMahon, Christopher G.
AU - Stuckey, B. G A
AU - Lording, D. W.
AU - Wittert, G. A.
AU - Murphy, A.
AU - Shin, J.
AU - Sutherland, P. D.
AU - Palmer, N. R.
AU - Lowy, M. P.
AU - Jesudason, D. R.
AU - Fredlund, P.
PY - 2005/2/1
Y1 - 2005/2/1
N2 - The efficacy and safety of tadalafil for the treatment of erectile dysfunction (ED) were assessed in a 6-month, randomised, double-blind, placebo-controlled study. Australian men with mild, moderate or severe ED of organic, psychogenic or mixed aetiology were randomised to tadalafil 20 mg as needed (n = 93) or placebo (n = 47). Efficacy assessments included the international index of erectile function (IIEF) and the sexual encounter profile (SEP) diary. Tadalafil significantly improve erectile function compared with placebo (p < 0.001, all measures). At the end of the study, the mean per-patient proportion of successful sexual intercourse attempts (SEP question three) was 73.5% for patients treated with tadalafil and 26.8% for placebo-treated patients. Improved erections were reported by 78% of tadalafil-treated patients compared to 12.8% of placebo-treated patients. The most common treatment-emergent adverse events - headache and dyspepsia - were generally mild or moderate. Tadalafil was effective and well tolerated in Australian men with mild to severe ED.
AB - The efficacy and safety of tadalafil for the treatment of erectile dysfunction (ED) were assessed in a 6-month, randomised, double-blind, placebo-controlled study. Australian men with mild, moderate or severe ED of organic, psychogenic or mixed aetiology were randomised to tadalafil 20 mg as needed (n = 93) or placebo (n = 47). Efficacy assessments included the international index of erectile function (IIEF) and the sexual encounter profile (SEP) diary. Tadalafil significantly improve erectile function compared with placebo (p < 0.001, all measures). At the end of the study, the mean per-patient proportion of successful sexual intercourse attempts (SEP question three) was 73.5% for patients treated with tadalafil and 26.8% for placebo-treated patients. Improved erections were reported by 78% of tadalafil-treated patients compared to 12.8% of placebo-treated patients. The most common treatment-emergent adverse events - headache and dyspepsia - were generally mild or moderate. Tadalafil was effective and well tolerated in Australian men with mild to severe ED.
KW - Erectile dysfunction
KW - Impotence
KW - Oral pharmacotherapy
KW - Phosphodiesterase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=20044362732&partnerID=8YFLogxK
U2 - 10.1111/j.1742-1241.2005.00451.x
DO - 10.1111/j.1742-1241.2005.00451.x
M3 - Article
C2 - 15854188
AN - SCOPUS:20044362732
VL - 59
SP - 143
EP - 149
JO - International Journal of Clinical Practice
JF - International Journal of Clinical Practice
SN - 1368-5031
IS - 2
ER -